JP2022552156A5 - - Google Patents
Info
- Publication number
- JP2022552156A5 JP2022552156A5 JP2022520588A JP2022520588A JP2022552156A5 JP 2022552156 A5 JP2022552156 A5 JP 2022552156A5 JP 2022520588 A JP2022520588 A JP 2022520588A JP 2022520588 A JP2022520588 A JP 2022520588A JP 2022552156 A5 JP2022552156 A5 JP 2022552156A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- salt according
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910684P | 2019-10-04 | 2019-10-04 | |
| US62/910,684 | 2019-10-04 | ||
| PCT/IB2020/059274 WO2021064677A1 (en) | 2019-10-04 | 2020-10-02 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552156A JP2022552156A (ja) | 2022-12-15 |
| JP2022552156A5 true JP2022552156A5 (https=) | 2023-10-11 |
Family
ID=73014547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520588A Pending JP2022552156A (ja) | 2019-10-04 | 2020-10-02 | ヒト免疫不全ウイルスの複製阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230013823A1 (https=) |
| EP (1) | EP4038061A1 (https=) |
| JP (1) | JP2022552156A (https=) |
| AR (1) | AR120150A1 (https=) |
| TW (1) | TW202128648A (https=) |
| WO (1) | WO2021064677A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541055B2 (en) | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| EP3849982A1 (en) * | 2018-09-14 | 2021-07-21 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) * | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US11541055B2 (en) * | 2018-10-24 | 2023-01-03 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2971987T3 (es) * | 2018-10-24 | 2024-06-10 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| JP7500555B2 (ja) * | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210395248A1 (en) * | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| EP4038068A1 (en) * | 2019-10-01 | 2022-08-10 | VIIV Healthcare UK (No.5) Limited | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| EP4038064B1 (en) * | 2019-10-01 | 2024-02-21 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| US20220370451A1 (en) * | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
| EP4114527A1 (en) * | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| BR112022020933A2 (pt) * | 2020-04-15 | 2022-12-06 | Viiv Healthcare Uk No 5 Ltd | Inibidores de replicação do vírus da imunodeficiência humana |
| MX2024004551A (es) * | 2021-10-13 | 2024-06-26 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicacion del virus de inmunodeficiencia humana. |
-
2020
- 2020-09-30 TW TW109134208A patent/TW202128648A/zh unknown
- 2020-10-02 EP EP20797180.5A patent/EP4038061A1/en not_active Withdrawn
- 2020-10-02 WO PCT/IB2020/059274 patent/WO2021064677A1/en not_active Ceased
- 2020-10-02 US US17/763,161 patent/US20230013823A1/en not_active Abandoned
- 2020-10-02 AR ARP200102746A patent/AR120150A1/es not_active Application Discontinuation
- 2020-10-02 JP JP2022520588A patent/JP2022552156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022552156A5 (https=) | ||
| DK2997019T3 (en) | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B | |
| JP2021169499A5 (https=) | ||
| JP2019069941A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| KR102519536B1 (ko) | 트리시클릭 회전장애이성질체 화합물 | |
| TW202321201A (zh) | 化合物及其用途 | |
| JP7222590B2 (ja) | ３－アザビシクロ［３，１，１］ヘプタン誘導体及びこれを含む薬学的組成物 | |
| JP2022551254A5 (https=) | ||
| JP6469214B2 (ja) | Ｎ−アシル−（３−置換）−（８−置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジンの新規キラル合成 | |
| JP2013533291A5 (https=) | ||
| JP7797486B2 (ja) | 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| CN117715906A (zh) | 胰高血糖素样肽-1受体调节剂及其用途 | |
| CN114105950B (zh) | 吡唑类化合物及其应用 | |
| CN105452259A (zh) | 三环苯并氧杂硼化合物、其制备方法与应用 | |
| WO2015172732A1 (zh) | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 | |
| TW202233614A (zh) | 作為激酶抑制劑之三唑并吡啶化合物 | |
| WO2021064677A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| CN118791481A (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 | |
| WO2017202357A1 (zh) | 一种三氟甲基取代的吡喃衍生物的制备方法 | |
| KR20250038236A (ko) | 코로나바이러스 감염 치료용 화합물 | |
| CN110698380B (zh) | 一种内酰胺衍生物及其制备方法与应用 | |
| KR20230128511A (ko) | 신규한 오토택신 억제제 | |
| WO2016196932A1 (en) | Process for preparing substituted tetracyclic heterocycle compounds | |
| CN116134025B (zh) | 酰胺膦氧类衍生物及其制备方法和用途 | |
| JPH07242670A (ja) | ピロロ［３，２−ｅ］ピラゾロ［１，５−ａ］ピリミジン誘導体及びこれを含有する循環器系疾患治療剤 |